Gene · 92521
Papers3,158
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
621 to 640 of 3,158
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| SARS-CoV-2 3CLpro mutations selected in a VSV-based system confer resistance to nirmatrelvir, ensitrelvir, and GC376. | Sci Transl Med | 2023 | 36194133 | PubTator, text mining | PubMed |
| Searching for potential inhibitors of SARS-COV-2 main protease using supervised learning and perturbation calculations. | Chem Phys | 2023 | 36188488 | PubTator, text mining | PubMed |
Using In Silico Bioinformatics Algorithms for the Accurate Prediction of the Impact of Spike Protein Mutations on the Pathogenicity, Stability, and Functionality of the SARS-CoV-2 Virus and Analysis of Potential Therapeutic Targets. | Biochem Genet | 2023 | 36173498 | PubTator, text mining | PubMed |
| Expediting the drug discovery for ideal leads against SARS-CoV-2 via molecular docking of repurposed drugs. | J Biomol Struct Dyn | 2023 | 36165445 | PubTator, text mining | PubMed |
| SARS-CoV-2-encoded inhibitors of human LINE-1 retrotransposition. | J Med Virol | 2023 | 36085352 | PubTator, text mining | PubMed |
| In silico Identification of Novel SARS-CoV-2 Main Protease and Nonstructural Protein 13 (nsp13) Inhibitors through Consensus Docking and Free Binding Energy Calculations. | Comb Chem High Throughput Screen | 2023 | 35984023 | PubTator, text mining | PubMed |
| COVID-19 and pregnancy: clinical outcomes; mechanisms, and vaccine efficacy. | Transl Res | 2023 | 35970470 | PubTator, text mining | PubMed |
| Deep learning application detecting SARS-CoV-2 key enzymes inhibitors. | Cluster Comput | 2023 | 35874186 | PubTator, text mining | PubMed |
| Structure basis for inhibition of SARS-CoV-2 by the feline drug GC376. | Acta Pharmacol Sin | 2023 | 35773339 | PubTator, text mining | PubMed |
| Setomimycin as a potential molecule for COVID‑19 target: in silico approach and in vitro validation. | Mol Divers | 2023 | 35622309 | PubTator, text mining | PubMed |
| Interferon antagonists encoded by SARS-CoV-2 at a glance. | Med Microbiol Immunol | 2023 | 35366686 | PubTator, text mining | PubMed |
| Comorbidities and clinical complications associated with SARS-CoV-2 infection: an overview. | Clin Exp Med | 2023 | 35362771 | PubTator, text mining | PubMed |
| Phytonutrient Inhibitors of SARS-CoV-2/NSP5-Encoded Main Protease (Mpro) Autocleavage Enzyme Critical for COVID-19 Pathogenesis. | J Diet Suppl | 2023 | 34821532 | PubTator, text mining | PubMed |
| Natural compounds may contribute in preventing SARS-CoV-2 infection: a narrative review. | Food Sci Hum Wellness | 2022 | 38621001 | PubTator, text mining | PubMed |
| The emergence of SARS-CoV-2 variants of concern in Australia by haplotype coalescence reveals a continental link to COVID-19 seasonality. | Methods Microbiol | 2022 | 38013929 | PubTator, text mining | PubMed |
| Proteomics research of SARS-CoV-2 and COVID-19 disease. | Med Rev (2021) | 2022 | 37724330 | PubTator, text mining | PubMed |
| A systematic review of RdRp of SARS-CoV-2 through artificial intelligence and machine learning utilizing structure-based drug design strategy. | Turk J Chem | 2022 | 37720604 | PubTator, text mining | PubMed |
| Development of Ultrapure and Potent Tannic Acids as a Pan-coronal Antiviral Therapeutic. | ACS Pharmacol Transl Sci | 2022 | 37582235 | PubTator, text mining | PubMed |
| SARS-CoV-2 modulation of RIG-I-MAVS signaling: Potential mechanisms of impairment on host antiviral immunity and therapeutic approaches. | MedComm Futur Med | 2022 | 37521851 | PubTator, text mining | PubMed |
| Peptidic Sulfhydryl for Interfacing Nanocrystals and Subsequent Sensing of SARS-CoV-2 Protease. | Chem Mater | 2022 | 37406055 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/92521/papers?page=32